OP0130 Risk of cancer in patients with psoriasis/psoriatic arthritis: a population-based study in the province of british columbia. (12th June 2018)

• Record Type: Journal Article
• Authors: Avina-Zubieta, J.A; Dominique, A.; Simon, T.A.; Tavakoli, H.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 115
• Page End: 116
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.3772
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts with PsO/PsA at population level are limited. Objectives: To assess the risk of cancer in pts with newly diagnosed PsO/PsA at the population level. Methods: We created a population-based matched retrospective cohort of PsO/PsA pts diagnosed between 1 January 1997 and 31 December 2012 using administrative health data from British Columbia, Canada. We identified all incident cases of PsO/PsA and an equal number of controls matched on sex, age and calendar year. PsO/PsA cases met ≥1 of the following: 1 diagnostic code for PsO/PsA by a rheumatologist/dermatologist; ≥2 diagnostic codes for PsO/PsA, ≥2 months apart in a 2 year period by a non-rheumatologist/dermatologist; or ≥1 hospitalisation with diagnostic code for PsO/PsA. We evaluated incident cancers during follow-up from the Cancer Registry in both cohorts. Adjusted risk of cancers was estimated using a generalised estimating equation extension of multivariate Poisson regression models. Results: We identified 81 568 incident cases of PsO/PsA (mean age 48.5 years [SD 17.8], 51.5% female). Individuals with PsO/PsA were at significantly higher risk of being diagnosed with 8/41 types of cancer examined, including eye and orbit (4 fold), female genital (3 fold), non-melanoma skin (2 fold), prostate (males; 1.1 fold) (table 1). Incidence of rectal and colon cancer was lower among PsO/PsA pts relative to the non-PsO/PsA cohort (table 1). PY=patient years Conclusions: This general population-based study demonstrates that pts with PsO/PsA have an increased risk of several types of cancer, and a decreased risk of rectal and colon cancer. This association highlights the need to further explore potential risk factors and pathways that contribute to these complications. Acknowledgements: This study received an unrestricted grant from Bristol-Myers Squibb for an investigator-initiated project in PsO/PsA. Disclosure of Interest: J. A. Avina-Zubieta Grant/research support from: Bristol-Myers Squibb, A. Dominique Employee of: Bristol-Myers Squibb, T. Simon Employee of: Bristol-Myers Squibb, H. Tavakoli Grant/research support from: Bristol-Myers Squibb